

PROOF COVER SHEET

Author(s): Wojciech Pluskiewicz, Piotr Adamczyk, Edward Franek, Ewa Sewerynek, Piotr Leszczynski, Hanna Wichrowska, Luiza Napiórkowska, Micha Stuss, Aleksandra Ptaszek, Tomasz Kostyk, Krzysztof S. Golba, Wioleta Garbacz, and Bogna Drozdowska

Article title: FRAX calculator and Garvan nomogram in male osteoporotic population

Article no: DAGM_A_875991

Enclosures: 1) Query sheet
2) Article proofs

Dear Author,

Please check these proofs carefully. It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.

The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the “Submit All Corrections” button.

Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution.

Contrib. No.	Prefix	Given name(s)	Surname	Suffix
1		Wojciech	Pluskiewicz	
2		Piotr	Adamczyk	
3		Edward	Franek	
4		Ewa	Sewerynek	
5		Piotr	Leszczynski	
6		Hanna	Wichrowska	
7		Luiza	Napiórkowska	
8		Micha	Stuss	
9		Aleksandra	Ptaszek	
10		Tomasz	Kostyk	
11		Krzysztof S.	Golba	
12		Wioleta	Garbacz	
13		Bogna	Drozdowska	

AUTHOR QUERIES

- Q1: Please provide the town and state abbreviation for StatSoft, Inc., USA cited in text.
- Q2: Please provide the town and country of origin (for other countries) identifying the headquarter location for MedCalc, Belgium cited in text.
- Q3: Please check and confirm Author name “Micha? Stuss”
- Q4: Please provide better quality artworks for figures 1, 2, 3 and 5.

ORIGINAL ARTICLE

FRAX calculator and Garvan nomogram in male osteoporotic population

Wojciech Pluskiewicz¹, Piotr Adamczyk², Edward Franek³, Ewa Sewerynek⁴, Piotr Leszczynski^{5,6}, Hanna Wichrowska³, Luiza Napiórkowska³, Michał Stuss⁴, Aleksandra Ptaszek⁴, Tomasz Kostyk⁵, Krzysztof S. Golba⁷, Wioleta Garbacz⁸, and Bogna Drozdowska⁹

¹Department and Clinic of Internal Diseases, Diabetology and Nephrology, Metabolic Bone Diseases Unit, Medical University of Silesia, Katowice, Poland, ²Department and Clinic of Paediatrics, Medical University of Silesia, Katowice, Poland, ³Department of Endocrinology, Medical Research Centre, Polish Academy of Science, Warsaw, Poland, ⁴Department of Endocrine Disorders and Bone Metabolism, Medical University, Lodz, Poland, ⁵Department of Rheumatology and Osteoporosis, Hospital J. Strusia, Poznan, Poland, ⁶Department of Physiotherapy, Rheumatology and Rehabilitation, Medical University, Poznan, Poland, ⁷Department of Cardiology, Medical University of Silesia, Katowice, Poland, ⁸Military Hospital, Gliwice, Poland, and ⁹Department of Pathomorphology, Medical University of Silesia, Katowice, Poland

Abstract

Purpose: The aim of the study was the presentation of osteoporotic fracture prediction in men. **Methods:** Eight-hundred and one men at the mean age of 70.8 ± 9.31 years were examined. The 10-year fracture prediction was established, using the FRAX™ calculator and Garvan nomogram. **Results:** The mean value for any fracture and hip fracture probabilities for FRAX were 7.26 ± 5.4% and 3.68 ± 4.25%, respectively. For Garvan fracture, risk values were 26.44 ± 23.83% and 12.02 ± 18.1%. The mean conformity for any fracture and hip fracture prediction for threshold of 20% (any fracture) and 3% (hip fracture) between Garvan and FRAX values was 55.8% (κ 0.041) and 79.65% (κ 0.599), respectively. ROC analyses showed the following areas under the ROC curves (AUC) for any fractures: FRAX 0.808 and Garvan nomogram 0.843 (p = 0.059). The AUC values for hip fractures were 0.748 for Garvan nomogram and for 0.749 FRAX, and did not differ. On the base of ROC data, the cut-off values with best accuracy to predict fractures for both methods were established. The conformity between methods for thresholds indicated by ROC analysis was 72.5% (κ 0.435) for any and 77.7% (κ 0.543) for hip fractures. **Conclusion:** The conformities between FRAX and Garvan in regard to hip fracture prediction were acceptable for a threshold of 3% and thresholds derived by ROC analysis, while for any fracture we recommend to use thresholds established by ROC analysis. This may suggest that the use of “universal” cut-off points is probably misleading.

Keywords

Fracture probability, FRAX, garvan nomogram, men, osteoporotic fracture

History

Received 7 July 2013
Revised 17 September 2013
Accepted 6 December 2013
Published online ■■■

Introduction

Osteoporosis, a serious health problem, is commonly considered as women’s disease. The majority of patients are women but, especially at later age stages, a significant part of all osteoporotic patients are men. The lifetime fracture risk in male subjects after the age of 40 amounts to 25% [1] and it is the men who are more frequently affected by serious consequences of experienced hip fracture(s). Also, the knowledge on bone metabolism and the awareness of osteoporosis as such are much weaker in men than in women. Osteoporosis is usually a clinically silent disease and, fairly often, an osteoporotic fracture comes up as its first manifestation. As it is

widely known, fracture history is one of the strongest risk factors for subsequent fractures [2], therefore, the main goal of any osteoporosis management is primary prevention of osteoporotic fractures. In order to properly set up prophylactic therapy, an accurate assessment of fracture probability or risk is an imperative. Recently, some prognostic models have been developed [3–6]. They are based on bone density measurements and take into consideration several defined clinical risk factors. In 2008, the WHO introduced a new fracture prediction tool (FRAX algorithm) to determine patient’s absolute fracture probability over a 10-year span [7]. The FRAX algorithm was developed by the WHO to be applicable in men and postmenopausal women; the National Osteoporosis Foundation (NOF) Clinician’s Guide focuses on its utility in postmenopausal women and men, aged >50. The current NOF Guide recommends to examine patients, taking into account their 10-year, FRAX-estimated probability scores of ≥3% for hip fracture and ≥20% for major osteoporotic

Address for correspondence: Prof. Wojciech Pluskiewicz, Department and Clinic of Internal Diseases, Diabetology and Nephrology – Metabolic Bone Diseases Unit in Zabrze, Medical University of Silesia in Katowice, 3-Maja 13/15 street, 41-800 Zabrze, Poland. Tel/Fax: +48 323704389. E-mail: osteolesna@poczta.onet.pl

fracture, in order to reduce their general fracture risk [8]. In turn, other authors have proposed algorithms for individualized 5-year and 10-year fracture risk prognoses, applicable for both women and men [9,10]. Obviously, neither fracture risk nor fracture probability assessment can entirely replace objective examination by a doctor, and only an absolute and comprehensive fracture risk prediction should be accounted for an appropriate management approach. The majority of published reports on fracture risk or probability address women, while a few papers only report studies (also scarce in their number) conducted in men [11–14].

The purpose of the reported cross-sectional study was to present and validate a 10-year fracture prediction in a group of 801 Polish men, determined by both the FRAX calculator [7] and the nomogram, proposed by Nguyen et al. from the Garvan Institute [9,10]. Although these two calculators conform each other with essential differences in their design (FRAX takes into account predicted lifetime, whereas Garvan algorithm is not adjusted for the risk of death in aging patients), from the clinical point of view they serve the same purpose, thus their comparison seems to be a justified and important goal.

Material

The studied group included 801 men at the mean age of 70.8 ± 9.31 years (the age range 55–94 years), evaluated at four osteoporotic outpatient clinics in four different centers. The entire study group comprised all successive patients, attending the clinics during the period from May 2009 to June 2010. The mean parameter values and SDs for weight, height and BMI were: 78.3 ± 13.2 kg, 169.7 ± 7.0 cm and 27.2 ± 3.91 kg/m², respectively.

A group of 218 men (27.2%) had, at least, one low-traumatic fracture at the age above 45, and 73 men (9.1%) presented with the history of multiple fractures, amounting to a total of 371 fractures in both groups. Therefore, a subgroup of 218 men include men with only one fracture ($n = 145$) and those who had more than one fracture ($n = 73$). The fractures were identified in the following skeletal sites: spine ($n = 206$), distal forearm ($n = 70$), tibia or fibula ($n = 39$), ribs ($n = 31$), proximal femur ($n = 16$), humerus ($n = 9$). Generally, the diagnosis of fracture was based on patients medical documentation including X-ray but in some patients spine fractures were self-reported because X-ray were not available. In patients who presented spine radiograms at the moment of recruitment, vertebral fractures were diagnosed according to widely accepted rules proposed by Genant.

The total number of patients with other clinical risk factors for osteoporosis, taken into consideration for fracture prediction in the studied cohort men, included those with hip fracture history in parents ($n = 46$, 5.7%), those on steroid therapy ($n = 82$, 10.3%), subjects with rheumatoid arthritis ($n = 35$, 4.4%), with secondary osteoporosis ($n = 43$, 5.8%), alcohol abuse ($n = 24$, 3.0%) and – finally – the number of patients with falls (one or more) during the last 12 months ($n = 90$, 11.2%).

Methods

Fracture prediction was assessed by the FRAX [5] calculator (<http://www.shef.ac.uk/FRAX>) and the Garvan nomogram

[6,7] (<http://www.garvan.org.au/bone-fracture-risk>). The 10-year fracture probability by the FRAX algorithm was based on age, BMI, fracture history in adulthood, hip fracture in parents' history, steroid use, rheumatoid arthritis, alcohol abuse, secondary osteoporosis and T-scores for femoral neck BMD (Bone Mineral Density). Fracture history was determined from patient reports and only fall fractures from standing height (an example typical for osteoporosis) were taken into consideration. T-scores, used for the calculations, were derived from NHANES III database for young females in all DXA devices were used. In order to calculate fracture probability by the FRAX algorithm, a model for the Polish male population was applied.

The 10-year fracture risk, estimated by Garvan nomogram, was based on the age, the number of prior fractures after 50, the number of falls during previous 12 months and T-score values for femoral neck BMD.

The FRAX calculator produces estimates for “major fractures”, in general confined to hip, humerus, spine and wrist, whereas the Garvan “all fractures” category is much broader and includes more fracture sites. This methodological difference was very important for the interpretation of results in our comparative study. As a rule, radiography was not used to confirm fracture occurrence.

A low fracture risk/probability for any fracture was defined when the value was $<20\%$, while high fracture risk/probability was accepted in cases of $\geq 20\%$. The respective values for hip fracture risk/probability were $<3\%$ and $\geq 3\%$.

The data for evaluation were acquired from bone densitometry centres in four Polish cities (Zabrze, Lodz, Warsaw and Poznan), covering the period from May 2009 to June 2010. In order to collect necessary data for fracture prediction, a structured questionnaire was used and the data were collected by physicians. All the subjects were submitted to hip BMD [g/cm²] measurements. Three GE Lunar and one Norland densitometer were used for that purpose.

The reported study received an approval of the local ethics committee.

Statistics

Statistical analysis was performed by means of the Microsoft Office Excel application, the Statistica 8 program (StatSoft, Inc., USA) and MedCalc 11.1.1.0 (MedCalc, Belgium), run on a PC computer. Fracture prediction was calculated for each studied subject, according to the FRAX algorithm [5] and given by Garvan nomogram [6,7]. Descriptive statistics are presented as the mean values and standard deviations (SDs). In order to apply an analysis of conformity assessment by both methods, the studied group was divided in the following ways [8]:

- two thresholds (levels) of fracture risk (Garvan) or probability (FRAX) in case of any fracture (low risk $<20\%$ and high risk $\geq 20\%$),
- two thresholds (levels) of fracture risk (Garvan) or probability (FRAX) in case of hip fracture (low risk $<3\%$ and high risk $\geq 3\%$).

The conformity was established separately for any fracture risk and for hip fracture risk, being defined as the same fracture risk threshold in either method (either low fracture

241 risk or high fracture risk for both calculators in particular
 242 patient). A reverse situation (low fracture risk, according to
 243 one method, and high fracture risk by the other) was classified
 244 as disconformity. The receiver-operating characteristics
 245 (ROC) curve analysis was applied: (1) to compare the
 246 diagnostic performance of the FRAX algorithm and Garvan
 247 nomogram in the assessment of any and hip fracture
 248 prediction and (2) to set a decision-making cut-off value of
 249 risk/probability which corresponded to the optimal threshold
 250 point of the ROC curve determined by Youden index. The
 251 calculation of the AUCs in ROC analysis has been done based
 252 on the dichotomous variable of fracture. As a negative case
 253 the patient without any prior fracture has been used, while as
 254 a positive case a patient with either any fracture or with
 255 hip fracture.

256 We also performed an additional analysis of conformity,
 257 using cut-off values, determined on the basis of the Youden
 258 index, established by ROC analysis for hip and any fracture
 259 instead of *a priori* assumed cut-off points at 3% and 20%.

260 For further analysis, it was assumed that the FRAX
 261 algorithm would be regarded as the reference method of
 262 fracture probability and the index of conformity was calculated
 263 as the percentage of men, classified at a given, FRAX-
 264 established risk level, who achieved the same risk threshold
 265 values in Garvan nomogram. The level of conformity (agree-
 266 ment) was presented as the percentage values and as the results
 267 of Cohen's κ test. The Wilcoxon test was used to compare the
 268 results of conformity expressed in percentage values before
 269 and after the correction based on ROC analysis.

270 A comparison of fracture predictive values was performed
 271 with the Mann-Whitney's U-test in subgroups with and
 272 without fracture history. All the results of statistical tests were
 273 regarded as statistically significant, when $p < 0.05$.

274

275 Results

276

277 Fracture probability or risk

278 The mean value for any and hip fracture probabilities in
 279 FRAX were $7.26 \pm 5.4\%$ and $3.68 \pm 4.25\%$, respectively. In
 280 Garvan estimates, the fracture risk values were $26.44 \pm$
 281 23.83% and $12.02 \pm 18.1\%$. Table 1 presents the numbers of
 282 men with low and high fracture predictive values for FRAX
 283 and Garvan nomogram.

284 Figure 1 shows fracture prediction changes with advancing
 285 age. The values from Garvan nomogram for any fracture were
 286 higher than those, obtained by the FRAX algorithm. However,
 287 that difference was not significant till the age of about 60.
 288 In hip fracture assessments, higher values were maintained
 289 till the age of 65, following the FRAX model. Then,
 290 with advancing age, the Garvan model values were higher.
 291 The average values of fracture probability or risk, derived for
 292 the whole study group, are presented in Figure 2.

293

294 Conformity with 20% threshold – any fracture

295

296 The mean conformity for any fracture prediction between
 297 Garvan and FRAX values was 55.8%, which corresponds to
 298 Cohen's κ value of 0.041, reflecting very poor level of
 299 agreement between methods. Of the 801 men, 428 were
 300 classified by both methods as low risk/probability and

Table 1. Subjects with low and high fracture probability by the FRAX
 calculator and those with low and high fracture risk by the Garvan
 algorithm.

Applied model	Number of men with low probability/risk	Number of men with high probability/risk
Any fracture probability by FRAX	776	25
Hip fracture probability by FRAX	451	350
Any fracture risk by Garvan	434	367
Hip fracture risk by Garvan	356	445





Figure 1. Changes in any fracture risk/probability (A) and hip fracture risk/probability (B) over age range. The curves demonstrate trends of the relations between calculated fracture risk/probability and age in individual subjects of the study cohort.

19 were classified by both methods as high risk/probability.
 348 demonstrated high risk, according to the Garvan method,
 and low probability, according to FRAX. Six were estimated
 with low Garvan and high FRAX values. These data are
 shown in Figure 3, part A.


Conformity with 3% threshold – hip fracture

The mean conformity for hip fracture prediction between
 Garvan and FRAX values was 79.65%, corresponding to

361 Figure 2. The average values of fracture
 362 probability (for FRAX) or fracture risk (for
 363 Garvan) derived from the whole study group.



380 Figure 3. Subgroups of men with or without
 381 indications for treatment, according to
 382 FRAX, based on the Polish reference
 383 population, and Garvan, established from
 384 "routine" cut-off values (20% in any fracture
 385 assessment and 3% in hip fracture assess-
 386 ment) for any fracture risk (A) or for hip
 fracture risk (B).



421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480

481 Cohen's κ value of 0.599. So the agreement between
482 methods for hip fracture was much better than that for any
483 fractures and could be classified at "moderate" (even close
484 to "good") agreement level. Of the 801 men, 322 were
485 classified by both methods at low risk/probability level, 316
486 were classified by both methods at high risk/probability level.
487 129 demonstrated high risk, according to Garvan and low
488 probability, according to FRAX. In 34, low Garvan and high
489 FRAX values were noted. These data are shown in Figure 3,
490 part B.

491 The most important factors, resulting in different classi-
492 fication levels (high Garvan and low FRAX values), included
493 falls and multiple fractures, and the observed opposite
494 situation was associated with a high number of clinical risk
495 factors, especially smoking, steroid use and rheumatoid
496 arthritis.

497 Fracture risk/probability stratified by fracture status

499 Table 2 presents fracture prediction levels, according to
500 fracture status, e.g. the presence or absence of fracture.
501 For both methods and for any and hip fracture, the fracture
502 risk or probability was significantly higher in men with
503 fracture(s) in history, in comparison with those without
504 such medical records. However, the probability levels,
505 estimated by both FRAX algorithms, approximately doubled
506 in the men with fractures in history, in comparison to those
507 without previous fracture episodes. The fracture risk level,
508 according to Garvan nomogram, was three times higher. One
509 can read from Table 2 that previous fracture remains the
510 strongest factor, influencing the risk/probability of consecu-
511 tive fracture.

512 Indication for treatment

514 Traditionally, the initiation of pharmacological treatment
515 is based mainly on T-score and/or the presence of typical
516 osteoporotic fracture. More recently, a 10-year fracture
517 probability or risk was proposed as the method of qualifica-
518 tion to treatment, and a threshold of 20% and 3% for any and
519 hip fracture, respectively, was recommended. We analyzed the
520 data to find out how many patients with the traditional
521 indication for treatment presented with high 10-year fracture
522 risk/probability.

523 Low T-score as an indication to treatment – any 524 fracture

527 In 251 men (31.33%), T-score value for femoral neck BMD
528 was equal or below -2.5 . Among 251 men with T-score
529 below -2.5 , only 24 revealed FRAX value above 20%. That
530 means that a significant majority of group studied ($n = 227$,
531 90.44%) would not be treated, despite low BMD values,

532 due low FRAX values. Opposite results are presented from
533 the Garvan algorithm and only 69 men (27.5%) were
534 classified in low fracture risk, despite low BMD levels, and
535 the majority of those 251 men ($n = 182$; 72.5%) achieved high
536 fracture risk score (the classification of men with low T-score
537 (below -2.5) at high fracture risk category more frequent
538 according to the Garvan algorithm in comparison to FRAX;
539 $\chi^2 = 205.5$, $df = 1$, $p < 0.0001$).

540 Low T-score as an indication for treatment – hip 541 fracture

542 An analysis, regarding hip fracture prediction, showed a much
543 better conformity for both methods. In FRAX, only 18
544 subjects (7.17%) with low BMD were classified into the group
545 with low fracture risk ($<3\%$). In turn, Garvan nomogram
546 revealed 22 men (8.76%) not qualifying to treatment despite
547 low BMD values (no significant difference between the
548 Garvan algorithm and FRAX calculator for proportion of men
549 with low and high fracture risk among patients with low
550 T-score; $\chi^2 = 0.43$, $df = 1$, $p < 0.51$).

551 Prior fracture as an indication to treatment – any 552 fracture

553 Among 218 men with prior fracture, only 17 (7.8%) presented
554 with the FRAX value above 20%, which means that a
555 significant majority of the patients ($n = 201$, 92.2%) would
556 not be treated, despite positive fracture history, due to low
557 FRAX values. Opposite results are presented by the Garvan
558 algorithm, by which only 39 men (17.9%) were classified at
559 low fracture risk level despite prior fracture and the majority
560 ($n = 179$; 82.1%) achieved high fracture risk score (the
561 classification of men with positive previous fracture history
562 at high fracture risk category more frequent according to the
563 Garvan algorithm in comparison to FRAX; $\chi^2 = 243.3$,
564 $df = 1$, $p < 0.0001$).

565 Prior fracture as an indication for treatment – hip 566 fracture


567 Analogous analysis for hip fracture cases showed better
568 conformity for both methods. In FRAX, 63 subjects (28.9%)
569 with fracture history were classified at low fracture risk
570 ($<3\%$). In Garvan nomogram, only 43 men (19.72%) would be
571 not treated despite prior fracture, whereas 175 (80.3%)
572 achieved high fracture risk score (in comparison to 155
573 (71.1%) by FRAX). Nonetheless, the differences between
574 methods remains significant as the classification of men with
575 positive previous fracture history at high fracture risk
576 category is slightly more frequent according to the Garvan
577 algorithm in contrast to FRAX; $\chi^2 = 4.99$, $df = 1$, $p < 0.05$).

533 Table 2. Assessment of fracture prediction stratified by fracture status.

534 Applied model	535 Men without fracture(s) 536 in history ($n = 583$)	535 Men with fracture(s) 536 in history ($n = 218$)	535 p
537 Any fracture probability by FRAX	537 $5.75 \pm 3.87\%$	537 $11.28 \pm 6.7\%$	537 <0.000001
538 Hip fracture probability by FRAX	538 $2.77 \pm 3.07\%$	538 $6.11 \pm 4.8\%$	538 <0.000001
539 Any fracture risk by Garvan	539 $17.82 \pm 14.7\%$	539 $49.48 \pm 27.92\%$	539 <0.000001
540 Hip fracture risk by Garvan	540 $7.7 \pm 12.66\%$	540 $23.62 \pm 24.45\%$	540 <0.000001

601 **ROC analyses**

602 In order to establish the accuracy of both methods, ROC
 603 analyses were performed for any and hip fractures. The
 604 statistical significance of the differences between the areas
 605 under ROC curves was assessed, using the method of
 606 DeLong et al. [15]. The area under ROC curve (AUC) for
 607 any fractures is presented in Figure 4, part A. The AUCs
 608 from ROC curve analysis were as follows: for the FRAX
 609 algorithm – 0.808 (95%CI 0.779–0.835), and for Garvan
 610 nomogram – 0.843 (95%CI 0.815–0.867). A borderline
 611 significant difference was observed between the obtained
 612 AUCs ($p=0.059$). The area under ROC curve for hip
 613 fractures is presented in Figure 4, part B. The AUCs from
 614 the ROC curve analysis were as follows: for the FRAX



617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657 Figure 4. A comparison of ROC (receiver-operating characteristic)
 658 curves, drawn for fracture probability, assessed by the FRAX nomogram
 659 and for fracture risk assessment by the Garvan nomogram. Part A of the
 660 Figure illustrates the probability/risk assessment for any fracture, while
 Part B for hip fracture.

algorithm – 0.749 (95% CI 0.718–0.779), and for Garvan 661
 nomogram – 0.748 (95%CI 0.716–0.778). The AUCs did not 662
 differ significantly. 663

Based on the ROC curve analysis, new cut-off values were 664
 established to predict fractures by each method. The cut-off 665
 values for any fracture were as follows: 20.2% (sensitivity, 666
 81.65%; specificity, 68.44%) for the Garvan method and 7.6% 667
 (sensitivity, 70.64%; specificity 77.36%) for FRAX. For hip 668
 fractures, the respective results were: 4.9% (with the sensi- 669
 tivity of 73.39% and the specificity of 63.46%) and 3.8% (with 670
 the sensitivity of 64.22% and the specificity of 76.67%). 671

672 Conformity assessment with cut-off values 673 from ROC analysis 674

675 Since the ROC analysis prompted other (i.e. at the level of
 676 20% for any fracture and 3% for hip fracture) than routinely
 677 accepted cut off points between the patients with low and high
 678 fracture risks, we decided to re-establish the conformity
 679 between methods, using our own calculated cut-off points
 680 (according to the values given in *ROC analyses* section). 681


When the patients were classified at low or high fracture 682
 risk, according to thresholds indicated by ROC analysis
 683 (different cut-off points for FRAX and Garvan method), the
 684 conformity between the methods was 72.5% (κ 0.435 –
 685 moderate agreement between methods) for any fracture and
 686 77.7% (κ 0.543 – also moderate agreement between methods)
 687 for hip fracture. Figure 5 presents the numbers of men,
 688 classified at low and high fracture risk level, according to both
 689 methods and with cut-off points, established in the ROC
 690 analysis. When our ROC analysis-based conformity was
 691 compared by the Wilcoxon test to conformity assessed by
 692 ‘‘routine’’ criteria, a significant improvement was observed in
 693 the conformity between the methods for any fracture
 694 ($p<0.0001$) and no change for hip fracture conformity. 695

696 Discussion 697

In the reported study, data of a 10-year fracture prediction in 698
 men are presented, with regards to some significant clinical 699
 points (age-related changes, the conformity in respect to 700
 established therapeutic thresholds, the influence of prior 701
 fracture(s), ROC analysis), assessed by the FRAX algorithm 702
 and Garvan nomogram, providing fairly unexpected results; 703
 both methods provided any fracture prediction with poor 704
 conformity (agreement) of 55.8% (κ 0.041). In turn, the 705
 comparisons for hip fracture prediction, with the value of 706
 79.65% (κ 0.599), demonstrated a fairly good agreement 707
 level. However, the use of cut-off values, which corresponded 708
 to an optimal threshold point from ROC curve analysis, 709
 improved significantly the conformity for any fracture, while 710
 the conformity for hip fracture was almost the same. These 711
 results suggest that treatment decision should be based rather 712
 on the thresholds for fracture prediction, defined for a specific 713
 population, instead of fixed criteria. 714

The conformity level, obtained in the reported study, 715
 should be compared with the recent results of a similar 716
 analysis, performed in a group of 2012 Polish women [16]. In 717
 that study, carried out with the use of the US Caucasian 718
 FRAX model and the Garvan algorithm (at that time, the 719
 Polish FRAX was not yet available), the conformity level was 720

721 Figure 5. Subgroups of men with or without
722 indications for treatment, according to
723 FRAX, based on the Polish reference popu-
724 lation, and by the Garvan method, using the
725 cut-off values, calculated from ROC curves
726 (for details see the text) for any fracture risk
(A) or for hip fracture risk (B).



762 79.1% for any and 79.5% for hip fracture prediction. The
763 currently obtained data for men are much weaker for any
764 fracture and almost the same for hip fracture prediction. In
765 both studies, the values of 3% for hip and 20% for any fracture
766 were used as the thresholds for treatment onset, according to
767 the widely known recommendations [8]. In our previous
768 study, we did not use any cut-off value from ROC analysis, so
769 we cannot provide any more comparisons. One may say that
770 conformity at the level of around 80% is acceptable in daily
771 practice but it is still low with regards to the “any fracture”
772 criterion, which requires a special attention.

773 ROC analysis provides important data on the clinical
774 utility of the used methods. In our previous study [16], we
775 obtained AUC for any fracture at 0.833 and for FRAX US,
776 0.879 for Garvan nomogram, while for the hip, the respective
777 values were 0.726 and 0.850, respectively. AUC values for
778 women were significantly higher for Garvan nomogram. In
779 the group of men, when compared with the group of women
780 (see our previously published report), we obtained: lower

822 AUC values for either method (FRAX or Garvan) in cases of
823 any fracture risk assessment, while higher AUC values for
824 FRAX and lower AUC values for the Garvan algorithm were
825 noted in cases of hip fracture assessment risk. Generally,
826 AUCs were lower for hip than for any fractures, just like in
827 women. Our AUCs were higher than the respective values in
828 a recent, 2-year prospective international study in 19 586
829 postmenopausal women [17]. However, in the cited study,
830 BMD was not included.

831 Ten-year fracture probability was assessed in male popu-
832 lations by some authors [11–14]. In a study by Sandhu et al.
833 [11], in a group of 56 men, FRAX US and FRAX UK were
834 used along with Garvan algorithms. The general fracture risk
835 was higher for Garvan nomogram than for FRAX algorithm
836 results (no data were provided for hip fracture risk), what is
837 comparable with our study. Compatibility with the used
838 method was determined, using the correlation of 0.6 between
839 FRAX and Garvan data. Unfortunately, no separate data were
840 presented for hip and any fracture. Furthermore, no separate

841 data were presented for men and women and the concordance
842 of fracture prediction was shown by simple correlation
843 analysis, not as in our methodology, showing the conformity
844 with regards to therapeutic decision thresholds. As expected,
845 the Garvan model yielded a higher average prediction of
846 major fracture occurrence in the fracture group, while the
847 FRAX algorithm did not. In the reported study, we
848 demonstrated that all the values of fracture prediction,
849 established by the FRAX algorithm and Garvan nomogram,
850 were significantly higher for all the variables. The authors
851 also presented AUCs for Garvan and FRAX-US algorithms of
852 0.76 and 0.54, respectively. Unfortunately, no separate AUCs
853 were provided for any or hip fractures. Irrespective of that, the
854 AUC – as observed in our study – seemed to be higher. The
855 authors drew a conclusion that the FRAX algorithm is a weak
856 (rather useless) fracture risk assessment tool in men.

857 In a recent study, performed in 115 men, treated by
858 androgen deprivation therapy (ADT) for localized prostate
859 cancer, the necessity of treatment was verified, using low
860 BMD and FRAX values [12]. The authors found that 33% of
861 men on ADT had osteoporosis of spine, hip or forearm,
862 confirmed by dual-energy X-ray absorptiometry (DXA), thus
863 requiring an appropriate treatment. Using the FRAX tool in
864 cases of corrected femoral neck, T-score identified only 17%
865 of treatment demanding cases and, if calculated without
866 femoral neck, 54% were identified as treatment needing cases.

867 In 363 men, treated with ADT for prostate cancer [13], a
868 10-year fracture probability was established by the FRAX
869 algorithm, identifying a higher proportion of men in need
870 of treatment than the traditional threshold of T-score -2.5
871 or less.

872 Recently, the performance of the FRAX algorithm system
873 was independently assessed in a large clinical cohort of
874 36730 women and 2873 men from the Manitoba Bone
875 Density Program database [14]. In the 10-year Kaplan–Meier
876 estimate for hip fractures in men, the observed risk was 3.5%,
877 with predictive value of 2.9% and any fracture risk was 10.7%
878 with predictive value of 8.4%. Fracture discrimination, based
879 upon ROC curve analysis, was comparable to the published
880 meta-analyses with the area under the ROC curve for
881 osteoporotic fracture prediction of 0.694 (95% CI 0.684–
882 0.705) for the FRAX algorithm with BMD and for hip
883 fractures of 0.830 (95% CI 0.815–0.846), both of which were
884 better than the FRAX algorithm results without BMD or
885 with BMD alone. The authors concluded that the Canadian
886 FRAX tool, calibrated on national hip fracture data, generated
887 fracture risk predictions that were generally consistent with
888 observed fracture rates across a wide range of risk categories.
889 AUC values for any fracture were smaller than in our study
890 (0.694 versus 0.808 and 0.843), while for hip fractures, AUC
891 was higher (0.830 versus 0.748–0.749).

892 The reported study had several limitations. The Garvan
893 nomogram values were calculated, based on the Australian
894 male population, posing a certain risk of obvious differences
895 between male populations in Australia and Poland. Because
896 FRAX calculator produces estimates for “major fractures”,
897 that are limited to hip, humerus, spine and wrist, where the
898 Garvan “all fracture” includes more fracture sites, the
899 divergences between any fracture risks may, at least, be
900 partially due to these methodological differences. In the FRAX

algorithm approach, osteoporotic fracture(s) in adulthood 901
should be taken into consideration, while in Garvan nomo- 902
gram, fracture(s) after the age of 50 should be included. We did 903
not verify fracture occurrence by the use of radiograms, thus 904
certain fractures, especially silent spine fractures, could have 905
been left unidentified. The authors of the FRAX algorithm 906
propose to use it only in treatment-naive subjects, while a 907
certain part of our population included men on antiresorptive 908
therapy. They were included because we were not interested to 909
follow-up patients and longitudinal modifications of fracture 910
risk by the therapy do not interfere with a single comparison of 911
both methods. We studied male outpatients only and this 912
population may not be representative for the general popula- 913
tion. One should also consider the fact that the lack of a cross- 914
calibration procedure among the used densitometric scanners 915
may have significantly affected the results of the study. And, 916
finally, and important methodological difference between 917
FRAX and Garvan methods should be presented. FRAX 918
takes into account epidemiological data, including life expect- 919
ancy in each population, while Garvan nomogram does not 920
include this factor. Therefore, in fact, the FRAX algorithm 921
establishes fracture probability (life expectancy is taken into 922
consideration) and the Garvan algorithm estimated fracture 923
risk (life expectancy is not taken into consideration). This 924
important methodological difference probably decreases the 925
conformity between both methods. This age-dependent dis- 926
crepancy between methods may also be, at least partially, 927
responsible for quite high ratio of men with low FRAX value 928
despite of low T-score for femoral neck in the case of any 929
fracture probability. 930

The part of the manuscript regarding the ROC analysis and 931
comparing of AUCs for both methods would be perfect if we 932
gathered longitudinal data in follow-up lasting for 10 years. 933
Such longitudinal data would be necessary, if we aimed to 934
establish sensitivity and specificity for each method separ- 935
ately. But, our aim in this part of the manuscript was to justify 936
the thesis that each diagnostic tool needs to be validated 937
individually and cut-off points (between high and low fracture 938
risk) established for one method in one specific population 939
cannot be directly implemented for other calculators or 940
other ethnic groups. In such analysis, retrospective data are 941
sufficient enough. 942

The question of a limited value of comparative studies, 943
focusing on the validation of different fracture risk or 944
probability calculators, was discussed in detail by Kanis 945
et al. in the recently published opinion paper [18]. But, 946
regardless of all the presented criticisms, one should agree 947
that the direct comparison of different calculators is still 948
justified by the fact that those diagnostic tools are dedicated 949
to the same practical applications. The fact that they lead to 950
different results makes a good starting point to understand 951
the methodological differences in their design. It also 952
provides a message that the estimations, obtained in each 953
calculator, have to be interpreted in a bit different way, 954
although they both are intended for the same application. This 955
conclusion, derived from our study, seems to have a 956
significant practical value. 957

Our study also has strengths: we were successful to get a 958
relatively large study group of men in a wide age range, 959
recruited from four medical centres. Also, the number of risk 960

961 factors, present in the studied men, enabled a reliable fracture
962 risk and probability assessment.

963 Concluding, in general, both methods comparably predict
964 fractures in regard to hip fracture. In the case of any fracture,
965 the level of conformity between both methods is much lower
966 (using the threshold of 20%), suggesting that the FRAX
967 algorithm leads to fracture risk underestimation. However,
968 when we reclassified our patients at low or high fracture risk
969 level, according to the new cut-off points based on ROC
970 analysis, the conformity for any fracture improved signifi-
971 cantly. This may be suggestive of a somewhat misleading
972 character of “universal” cut-off point, however, it is still
973 necessary to establish a cut-off point, according to the results
974 of the sensitivity-specificity analysis, separately for each
975 method and for the reference population.

976 Declaration of interest

977 The authors declare they have no competing interests or other
978 interests that might be perceived to influence the interpret-
979 ation of the article.
980

981 References

- 982 1. Nguyen ND, Ahlborg HG, Centre RJ, et al. Residual lifetime risk of
983 fractures in women and men. *J Bone Miner Res* 2007;22:781–8.
- 984 2. Kanis JA on behalf of the WHO Scientific Group. Assessment of
985 osteoporosis at the primary health care level. Sheffield, UK:
986 University of Sheffield; 2007.
- 987 3. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for
988 predicting fracture risk in postmenopausal women. *Osteoporos Int*
989 2001;12:519–28.
- 990 4. van Staa TP, Geusens P, Kanis JA, et al. A simple clinical score for
991 estimating the long-term risk of fracture in postmenopausal women.
992 *QJM* 2006;99:673–82.
- 993 5. Ettinger B, Hilier TA, Pressman A, et al. Simple computer model
994 for calculating and reporting 5-year osteoporotic fracture risk in
995 postmenopausal women. *J Womens Health (Larchmt)* 2005;14:
996 159–71.

- 997 6. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic
998 fracture in men and women in England and Wales: prospective
999 derivation and validation of QFractureScores. *Br Med J* 2009;339:
1000 b4229.
- 1001 7. Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment
1002 of fracture probability in men and women from the UK. *Osteoporos*
1003 *Int* 2008;19:385–97.
- 1004 8. Siris ES, Baim S, Nattiv A. Primary care use of FRAX: absolute
1005 fracture risk assessment in postmenopausal women and older men.
1006 *Postgrad Med* 2010;122:82–90.
- 1007 9. Nguyen ND, Frost SA, Centre JR, et al. Development of a
1008 nomogram for individualizing hip fracture risk in men and women.
1009 *Osteoporos Int* 2007;18:1109–17.
- 1010 10. Nguyen ND, Frost SA, Centre JR, et al. Development of prognostic
1011 nomograms for individualizing 5-year and 10-year fracture risks.
1012 *Osteoporos Int* 2008;19:1431–44.
- 1013 11. Sandu SK, Nguyen ND, Centre JR, et al. Prognosis of fracture:
1014 evaluation of predictive accuracy of the FRAX™ algorithm and
1015 Garvan nomogram. *Osteoporos Int* 2010;21:863–71.
- 1016 12. Adler RA, Hastings FW, Petkov VI. Treatment thresholds for
1017 osteoporosis in men on androgen deprivation therapy: T-score
1018 versus FRAX. *Osteoporos Int* 2010;21:647–53.
- 1019 13. Saylor PJ, Kaufman DS, Michaelson MD, et al. Application of a
1020 fracture risk algorithm to men treated with androgen deprivation
1021 therapy for prostate cancer. *J Urol* 2010;183:2200–5.
- 1022 14. Leslie WD, Lix LM, Johansson H, et al.; Manitoba Bone Density
1023 Program. (2010) Independent clinical validation of a Canadian
1024 FRAX((R)) tool: fracture prediction and model calibration. *J Bone*
1025 *Miner Res* 2010;25:2350–8.
- 1026 15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing
1027 the areas under two or more correlated receiver operating
1028 characteristic curves: a nonparametric approach. *Biometrics* 1988;
1029 44:837–45.
- 1030 16. Pluskiewicz W, Adamczyk P, Franek E, et al. Ten-year probability
1031 of osteoporotic fracture in 2012 Polish women assessed by FRAX
1032 and nomogram by Nguyen et al.-Conformity between methods and
1033 their clinical utility. *Bone* 2010;46:1661–7.
- 1034 17. Sambrook PN, Flahive J, Hooven FH, et al. Predicting fractures in
1035 and international cohort using risk factor algorithms without BMD.
1036 *J Bone Miner Res* 2011;26:2770–7.
- 1037 18. Kanis JA, Oden A, Johansson H, McCloskey E. Pitfalls in
1038 the external validation of FRAX. *Osteoporos Int* 2012;23:
1039 423–31.

1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020

1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080